|
|
|
|
| LEADER |
01588nam a2200325 u 4500 |
| 001 |
EB001865520 |
| 003 |
EBX01000000000000001029600 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
190504 r ||| eng |
| 245 |
0 |
0 |
|a Clinical review report: Eliglustat (Cerdelga)
|h Elektronische Ressource
|b (Sanofi Genzyme) : indication: Gaucher disease type 1
|
| 246 |
3 |
1 |
|a Eliglustat (Cerdelga)
|
| 246 |
3 |
1 |
|a Clinical review report for Cerdelga
|
| 250 |
|
|
|a Version 1.0
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2017, August 2017
|
| 300 |
|
|
|a 1 PDF file (93 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Adult
|
| 653 |
|
|
|a Canada
|
| 653 |
|
|
|a Enzyme Replacement Therapy / adverse effects
|
| 653 |
|
|
|a Cytochrome P-450 CYP2D6 Inhibitors / therapeutic use
|
| 653 |
|
|
|a Treatment Outcome
|
| 653 |
|
|
|a Gaucher Disease / drug therapy
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH common drug review
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK534691
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a The objective of this report was to perform a systematic review of the beneficial and harmful effects of eliglustat 84 mg capsules for the long-term treatment of adults with Gaucher disease type 1 (GD1) who are cytochrome P450 2D6 (CYP2D6) poor metabolizers, intermediate metabolizers, or extensive metabolizers
|